(Toronto, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the quarter ended October 31, 2016.
- 0 Comments
- FY2017